Lupin slipped 1.65% to Rs 1,371.10 at 14:25 IST on BSE, in volatile trade after announcing Q2 result during market hours today, 28 October 2014.
Meanwhile, the BSE Sensex was up 111.10 points, or 0.42%, to 26,864
On BSE, so far 2.89 lakh shares were traded in the counter, compared with an average volume of 77,412 shares in the past one quarter.
The stock was volatile. The stock hit a high of Rs 1,406.85 and low of Rs 1,322.65 so far during the day. The stock hit a record high of Rs 1,442.30 on 16 September 2014. The stock hit a 52-week low of Rs 841.10 on 21 November 2013.
The stock had outperformed the market over the past one month till 27 October 2014, rising 1.03% compared with 0.48% rise in the Sensex. The scrip also outperformed the market in past one quarter, gaining 23.49% as against Sensex's 2.4% rise.
The large-cap company has an equity capital of Rs 89.81 crore. Face value per share is Rs 2.
More From This Section
On a consolidated basis, Lupin's net profit grew by 55.11% to Rs 630.04 crore on 19.43% rise in total income to Rs 3283.64 crore in Q2 September 2014 over Q2 September 2013.
Lupin's operating profit jumped 26.2% to Rs 832.60 crore in Q2 September 2014 over Q2 September 2013. The operating profit margin (OPM) edged up to 26.7% in Q2 September 2014, from 25.1% in Q2 September 2013.
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin, said We have had a great first half driven by strong growth in US, India, Japan and our API business. Our research pipeline is evolving well and we expect significant developments in the dermatology and inhalation space in the quarters to come.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the third largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
Powered by Capital Market - Live News